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IN addition to administration of oxygen, diuretics, vasodilators, and anticoagulants, the support of severely impaired myocardial contractile function with positive inotropic agents represents a mainstay of therapy in critically ill patients. Irrespective of whether used in patients with acute decompensation of chronic heart failure (CHF), contractile dysfunction after myocardial infarction, or stunning after cardiac surgery, these drugs frequently improve contractility and relieve symptoms. Regarding clinical outcome, however, the results of many trials suggest substantial limitations of such drugs in the treatment of myocardial contractile dysfunction. 1 With the exception of digoxin, which has neutral effects on overall mortality, 2 currently available positive inotropic substances, including ␤ 1 -adrenoceptor agonists and phosphodiesterase (PDE) III inhibitors, have been found detrimental in the long-term treatment of heart failure because they contribute to the development of malignant ventricular tachyarrhythmias and increase the incidence of sudden cardiac death. 3, 4 In addition, recent studies also indicate that short-term administration of PDE III inhibitors is associated with a high incidence of treatment-related complications, e.g., atrial fibrillation and hypotension, 5 particularly when concomitant ischemia is present as in patients with ischemic cardiomyopathy. 6 The reasons for these disappointing findings may be related to the fact that, despite different primary sites of action, all of these drugs eventually enhance myocardial contractility by increasing intracellular levels of cyclic adenosine monophosphate (cAMP) in myocytes, whether generated by an increased rate of synthesis (␤ 1 -adrenoceptor agonists) or by a decreased rate of degradation (PDE III inhibitors), which promotes the release of Ca 2ϩ from the sarcoplasmic reticulum (SR) to the cytosol. Augmentation of intracellular Ca 2ϩ subsequently produces a temporary improvement in contractility at the expense of an increased myocardial energy consumption and oxygen demand, 7 which finally accelerates myocardial cell death. Furthermore, increased concentrations of cAMP and the subsequent change in intracellular Ca 2ϩ turnover are cardiotoxic and enhance electrophysiologic mechanisms that result in rhythm disturbances. 8 Accordingly, considerable research has been devoted to develop new approaches to positive inotropic therapy independent of the potentially deleterious mechanism of augmenting intracellular Ca 2ϩ availability. Theoretically, such approaches should enhance contractile force without increasing myocardial oxygen demand or the risk of cardiac arrhythmias. As the relation of intracellular Ca 2ϩ and corresponding tension of cardiac myofilaments may be impaired during pathophysiological conditions such as ischemia, acidosis, sepsis, or hypothermia, drugs have been developed that modulate this relation without actual alteration of intracellular Ca 2ϩ levels. 9 All of these "myofilament Ca 2ϩ sensitizers," including levosimendan, pimobendan, EMD 57033, ORG 30029, MCI-154, and others, share the ability to enhance contractility by increasing the sensitivity of the myofilaments to calcium although with different potencies, through diverse mechanisms and sites of action, and with varying degrees of parallel PDE inhibitory effects. 10 Among these, levosimendan is promising in the management of both acute and chronic left ventricular (LV) failure, because it is a potent Ca 2ϩ sensitizer, 10 has no negative impact on diastolic function, 11 has little potency for additional PDE inhibition at clinically recommended concentrations, 12 has neutral effects on heart rhythm, 13 and has advantages over dobutamine in long-term survival. 14 Levosi mendan was first approved in Sweden in 2000 and is currently in clinical use in approximately 30 countries, predominately in Europe and South America. The drug is in large phase III clinical studies in the United States (REVIVE) and Europe (SURVIVE) and has been granted fast-track status by the Food and Drug Administration. The European Society of Cardiology has adopted its use in the treatment of acute heart failure in 2001 15 and assigned it a class of recommendation IIa (i.e., conflicting evidence with weight in favor of usefulness), level of evidence B (i.e., data derived from a randomized clinical trial) in the treatment of symptomatic low-cardiac output heart failure secondary to cardiac systolic dysfunction without severe hypotension in 2005, 16 which is superior to catecholamines or PDE III inhibitors for this indication.
This review compares the different actions of standard positive inotropic drugs and Ca 2ϩ sensitizers. It also summarizes the current experimental and clinical knowledge of the use of levosimendan and gives practical recommendations with a special focus on the perioperative setting.
Mechanism of Myocardial Excitation-Contraction Coupling
When the myocyte sarcolemma depolarizes, extracellular Ca 2ϩ enters the cell, primarily through sarcolemmal voltage-gated L-type Ca 2ϩ channels. This action on its own is insufficient to produce contraction of the myofilaments but triggers the (passive) release of larger amounts of Ca 2ϩ from the SR to the cytosol ("calciuminduced Ca 2ϩ release"), 17 which subsequently initiates contraction. Contraction is performed by interaction of a variety of structural and regulatory proteins, including myosin, actin, tropomyosin, and the troponin complex (TnC, TnI, TnT). When cytosolic Ca 2ϩ is low during relaxation (approximately 10 Ϫ7 M), tropomyosin inhibits interaction between actin and myosin. Contraction is initiated when cytosolic Ca 2ϩ increases (approximately 10 Ϫ5 M), binds to TnC, and causes a conformational change of this protein. Subsequent activation of TnT removes tropomyosin and TnI from the adenosine triphosphate (ATP) reactive site, thus allowing actin to interact with myosin, a process known as cross-bridging. As long as Ca 2ϩ is bound to TnC, this energy-dependent process is repeatedly performed ("cross-bridge cycling") to generate contractile force. During basal states, Ca 2ϩ does not saturate the myofilaments, i.e., approximately 25% of full activation is achieved. This reserve of activation can be mobilized by increasing either the amount of Ca 2ϩ available for binding or the sensitivity of myofilaments to Ca 2ϩ . Relaxation is initiated both by phosphorylation of TnI and rapid removal of cytosolic Ca 2ϩ predominately by reuptake into the SR through the (energyrequiring) sarcoplasmic endoplasmic reticulum calcium adenosine triphosphatase isoform 2 (SERCA2). With each contraction-relaxation cycle, there is no net gain or loss of cellular Ca 2ϩ .
Importantly, the response of myofilaments to a specific intracellular concentration of Ca 2ϩ may be attenuated (i.e., "desensitization") by a variety of pathophysiologic conditions, including acidosis, 18 hypothermia, 19, 20 increased inorganic phosphate, 21 sepsis, 22 ischemia-reperfusion injury, 23 and myocardial stunning, 24 but also by pharmacologic ␤-adrenergic stimulation [25] [26] [27] or the presence of CHF with increased neurohormonal activation. Conversely, the sensitivity of contractile proteins to Ca 2ϩ may increase, e.g., by ␣-adrenergic receptor stimulation 27 or by administration of myofilament calcium sensitizers. 10
Mechanism of Action of Standard Inotropic Drugs
Drugs currently used to achieve positive inotropic effects in the perioperative setting include catecholamines, e.g., dobutamine, and PDE III inhibitors, e.g., milrinone. Although these substances have different sites of action, they ultimately initiate a cascade of events that stimulate contractility by increasing intracellular Ca 2ϩ concentration ( fig. 1 ). Binding of catecholamines to ␤ 1 -adrenergic receptors on the surface of myocytes activates adenylate cyclase, which generates cAMP from ATP. cAMP activates protein kinase A, which subsequently phosphorylates (i.e., attaches a phosphate group to) intracellular targets, including the voltage-gated Ltype Ca 2ϩ channel, phospholamban, and TnI. Phosphorylation of sarcolemmal voltage-gated L-type Ca 2ϩ channels enhances Ca 2ϩ entry into the cytosol. The increased activity of these channels further increases "trigger calcium," leading to greater activation of the calcium release channel (RyR2) in the SR and subsequent contraction (i.e., positive inotropic action of catecholamines and PDE III inhibitors). In contrast, phosphorylation of phospholamban activates SERCA2. This action increases the rate of Ca 2ϩ transport from the cytosol back into the SR during diastole and is therefore responsible for the positive lusitropic actions of catecholamines and PDE III inhibitors. Although this lusitropic action enhances relaxation, it is also crucial to ensure sufficient Ca 2ϩ availability from the SR for the next cellular depolarization and contributes to the overall gain in cardiac excitationcontraction coupling that adrenergic stimulation medi-ates. The consequences of this increased loading of the SR with Ca 2ϩ may be a key factor in the development of Ca 2ϩ -mediated arrhythmias. 8 Phosphorylation of TnI decreases the affinity of myofilaments for Ca 2ϩ and thereby also favors relaxation. 28 -30 Together, these effects provide an integrated response to ␤-adrenergic stimulation that increases myocardial contractility, while in parallel supports myocardial relaxation by desensitizing myofilaments and augmenting the active removal of Ca 2ϩ from the cytosol.
Cardiac glycosides, e.g., digoxin, selectively and reversibly inhibit the sarcolemmal Na ϩ -K ϩ adenosine triphosphatase in cardiac myocytes with a resultant modest increase in intracellular Na ϩ . This increase of Na ϩ subsequently inhibits extrusion of Ca 2ϩ from the cytosol into the extracellular compartment by the Na ϩ -Ca 2ϩ exchanger. Ca 2ϩ not extruded from the cytosol by this mechanism is stored in the SR and allows increased release of Ca 2ϩ during the next contraction. Digoxin is commonly not used to increase myocardial contractility in the perioperative period because of only modest positive inotropic effects and a small therapeutic range. As digoxin decreases atrioventricular nodal conduction, it is, along with amiodarone, however, useful in the control of ventricular rate during refractory atrial fibrillation. 31
Mechanism of Action of Levosimendan
Positive Inotropic Effects Myofilament Ca 2؉ Sensitization. Levosimendan enhances myocardial contractility by binding to the Nterminal lobe of cardiac TnC with a high affinity [32] [33] [34] and stabilizing the Ca 2ϩ -bound conformation of this regulatory protein. 32 Therefore, systolic interaction of actinmyosin filaments is prolonged without alteration of the rate of cross-bridge cycling. Other myofilament Ca 2ϩ sensitizers are bound to the TnC-Ca 2ϩ complex during both systole and diastole with improvement of systolic but possible impairment of diastolic function 35 due to facilitation of cross-bridging at diastolic Ca 2ϩ levels, whereas binding of levosimendan to TnC is dependent on the cytosolic Ca 2ϩ concentration, i.e., increases during systole but is relatively unchanged during diastole, when Ca 2ϩ levels decrease. 36 This mechanism may be the reason for the parallel enhancement of myocardial contractility and improvement of LV diastolic function without promoting arrhythmogenesis or alteration of myocardial oxygen demand in experimental 36 -38 and clinical 11, 39 studies.
Phosphodiesterase III Inhibition. In addition to myofilament Ca 2ϩ sensitization, levosimendan inhibits cardiac PDE, predominately PDE III, 40 in muscle strips from human hearts 41 and various animal models. 12, 40, 42 This effect is observed predominately at higher concentrations (Ͼ 0.3 M), 12, 43 but is not seen (0.03 M) or is less pronounced (0.1-0.3 M) at concentrations reflecting the clinically recommended therapeutic range of 0.03-0.3 M (i.e., 10 -100 ng/ml). 44, 45 Therefore, at concentrations of 0.03-0.1 M, levosimendan does not alter heart rate, cAMP levels, myocardial relaxation, 12 and cytosolic Ca 2ϩ as assessed by aequorin light transients, 37, 41 although it significantly increases myocardial contractility in guinea pig hearts 12 and shifts the graph of the relation between Ca 2ϩ and contractile force to the left. 37 These findings indicate that levosimendan mainly acts as a Ca 2ϩ sensitizer at concentrations of 0.03-0.1 M. Although 0.1-0.3 M levosimendan variably alters myocardial cAMP levels, heart rate, 32 P incorporation into phospholamban, 12 and aequorin light transients, 41 concentrations exceeding 0.3 M consistently increase heart rate, contraction (ϩdP/dt) and relaxation (ϪdP/dt) as well as partial phosphorylation of phospholamban 12 and aequorin light transients. 41 These findings suggest a contributing role of PDE inhibition at concentrations of levosimendan exceeding 0.3 M.
Important experimental and clinical differences between levosimendan and classic PDE inhibitors (e.g., milrinone), however, exist. First, milrinone has no Ca 2ϩ sensitizing effect, 46 but in contrast decreases the sensitivity of myofilaments to Ca 2ϩ through cAMP-dependent phosphorylation of TnI, whereas levosimendan has this action. 12 Second, milrinone consistently exerts positive inotropic effects in parallel with an increase in aequorin light emission (indicating influence on Ca 2ϩ transients), 41 whereas levosimendan at low concentrations does not have this effect despite production of positive inotropic effects, suggesting that levosimendan is more potent as a Ca 2ϩ sensitizer than as an inhibitor of PDE. 12, 47 Third, metabolism of levosimendan produces a long-lasting active metabolite, OR-1896, 48 which has similar Ca 2ϩ sensitizing properties like the parent compound 49 but a significantly lower potential to inhibit PDE III (40-fold less potent, 3-fold less selective). 40 Because levosimendan has a relatively short elimination half-life and the infusion is usually discontinued after 24 h, the sustained positive inotropic effects observed thereafter 50 suggest an important role of Ca 2ϩ sensitization of this metabolite. Fourth, in clinical practice, levosimendan does not increase the incidence of arrhythmias, 13 worsen ischemia, 51 or negatively influence patient outcome, 14, 51 whereas milrinone does. 4 -6 Vasodilation Levosimendan produces vasodilation in several vasculatures including coronary, 52-54 pulmonary, 55 renal, 56 splanchnic, 56 cerebral, 56 and systemic 57,58 arteries as well as saphenous, 59 portal, 60 and systemic 57,58 veins. The underlying mechanism of vasodilation has been extensively investigated 54,55 but has not yet been entirely clarified. Recent evidence proposes involvement of several systems or pathways in the vasodilating effects of levosimendan ( fig. 2 ). An important mechanism in vascular smooth muscle of systemic, coronary, 53, 61 and pulmonary 55 arteries is opening of potassium channels, including ATP-sensitive K ϩ (K ATP ) channels in small resistance vessels and Ca 2ϩ -activated K ϩ and voltagedependent K ϩ channels in large conductance vessels. 62, 63 Opening of these channels hyperpolarizes the membrane, inhibits inward Ca 2ϩ current, and activates the Na ϩ -Ca 2ϩ exchanger to extrude Ca 2ϩ . The resultant decrease in intracellular Ca 2ϩ produces vasorelaxation. Attenuation of levosimendan-induced dilation of coronary arteries during concomitant administration of the K ATP channel antagonist glibenclamide emphasizes the role of K ATP channels in this setting. 53, 61 A second mechanism involved in levosimendan-induced vasodilation is reduction of Ca 2ϩ sensitivity of the (TnC-lacking) contractile proteins in vascular smooth muscle. 64 This decrease in contractile force of vascular myofilaments occurs without a proportionate decrease in intracellular Ca 2ϩ . In addition, PDE inhibition has been proposed to contribute to levosimendan-induced vasodilation because of increases in cAMP in vascular smooth muscle. 65 This effect, however, predominately occurs at excessive doses (1 mM) of levosimendan, 54 whereas at 3 M, vasorelaxation is different from milrinone 64 and not affected by inhibition of protein kinase A at concentrations of 0.01-1 M. 47 Although the importance and relative contribution of each of these mechanisms of vasorelaxation is unclear and may be different in various vessels and dependent on the dose of levosimendan, an important role of K ϩ channel opening is obvious, whereas the role of PDE inhibition remains to be defined.
Hemodynamic Effects of Levosimendan
Levosimendan consistently increases cardiac output in experimental and clinical studies. Possible theoretical mechanisms of this action are modification of heart rate, improvement of cardiac performance, and vasodilation.
Heart Rate
Levosimendan dose-dependently (Ն 0.1 M) increased heart rate in several animal experiments, 12, 38, 42 healthy volunteers, 66 and patients with New York Heart Association (NYHA) functional class II-IV heart failure of ischemic etiology. 45 The mechanism of the occasionally observed early levosimendan-induced increase in heart rate is unknown but may be produced by compensatory vasodilation-induced activation of baroreceptor reflexes, 67 particularly after administration of a bolus. Conversely, studies demonstrate an initial neutral effect on heart rate after abandonment of a bolus, 68 concentrations (3-12 g/kg), 51, 66, 69 or oral administration of levosimendan. 70 In contrast, persistence of an increased heart rate after discontinuation of a 24-h infusion of levosimendan 48, 50 or after extended infusions for 7 days 71 suggests an important role of OR-1896, a metabolite of levosimendan, 48 which continues to accumulate after withdrawal of levosimendan. 50 In clinical practice, treatment of patients with normal or reduced ejection fraction but within the recommended dosages (6-to 24-g/kg bolus over 10-min, followed by an infusion of 0.05-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) 45 rarely produces positive chronotropy exceeding more than 10% from baseline 45 and is generally less marked in patients with severe heart failure. Accordingly, neutral or insignificant effects on heart rate were observed in patients with CHF, 45 cardiogenic shock, 72 and severe decompensated low-output heart failure 14, 58, 73 and after myocardial infarction, 51 but also in the perioperative period in patients undergoing surgical revascularization with normal 39 or compromised 74 ventricular function. In contrast, administration of high doses of levosimendan (36-g/kg bolus and infusion of 0.3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 over 6 h) in patients with a normal ventricular function increased heart rate after cardiopulmonary bypass, particularly after the bolus (ϩ24 beats/min) and during the first hour of infusion. 75 Therefore, changes in heart rate are obviously a function of dosage, intravascular volume status, and preexisting compromise of myocardial contractile function. 76 Taken together, modification of heart rate under clinical conditions and within the recommended doses 45 is unlikely to be an important mechanism of the increase in cardiac output produced by levosimendan.
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Cardiac Performance
Administration of levosimendan enhances cardiac performance in vitro, 41 in vivo, 76 and in clinical studies. 14, 58 For example, in patients with low-output heart failure, a 24-h administration of levosimendan (0.1-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) increased cardiac output by 1.09 l/min and decreased pulmonary capillary wedge pressure (PCWP) by 7 mmHg, whereas dobutamine (5-10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) changed these parameters by 0.80 l/min and 3 mmHg, respectively ( fig. 3 ). 14 These effects generally occur in a dose-dependent manner and are characterized by an increase in LV stroke volume and cardiac index in patients with severely compromised ventricular function. 58 In addition, improved cardiac performance has also been suggested by a significant decrease of circulating levels of amino terminal pro B-type natriuretic peptide after a 24-h infusion of levosimendan (0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in patients with decompensated CHF and a mean LV ejection fraction of approximately 25%. 77 Interestingly, the decrease of this neurohormonal marker was particularly pronounced 48 h after discontinuation of levosimendan treatment.
Although Ca 2ϩ sensitizers carry a potential risk of worsening diastolic function, 35 levosimendan decreased the time constant of isovolumic relaxation () in various experimental 38, 76, 78 and clinical 11 settings, indicating improvement rather than deterioration of diastolic function. In addition to these beneficial effects at rest, levosimendan treatment also improved LV systolic and diastolic performance during exercise in dogs with pacing-induced CHF. 79 These positive lusitropic effects may be related to the Ca 2ϩ dependence of Ca 2ϩ -bound sensitization of cardiac TnC, i.e., the contractile apparatus is sensitized in systole (when Ca 2ϩ is high) but not in diastole (when Ca 2ϩ is low) or alternatively due to PDE III inhibition.
Vasodilation
Vasodilation observed with administration of levosimendan is followed by numerous consequences. Pulmonary vasodilation decreases right heart filling pressures, 58 which, in context with positive inotropic 57 and increases blood flow to various tissues, including myocardium, gastric mucosa, 82 renal medulla, small intestine, and liver. 56 In the splanchnic area, levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation 82, 83 and increases portal venous blood flow and oxygen delivery in experimental septic shock. 84 Clinical consequences of levosimendan-induced vasodilation must be seen in context with the parallel improvement of cardiac performance. Although vasodilation may decrease mean arterial blood pressure, which compromises, for example, renal perfusion, the parallel increase in cardiac output frequently more than compensates this handicap. For example, renal function was improved after a 24-h infusion of levosimendan (0.1-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in patients with low-output heart failure as demonstrated by decreases of serum creatinine levels (Ϫ9 M) compared with infusions of dobutamine (5-10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ). 14
Anti-ischemic Effects of Levosimendan
Particularly during ischemia and reperfusion, administration of catecholamines and PDE III inhibitors produce detrimental side effects, e.g., atrial and ventricular tachyarrhythmias. 5, 6, 85, 86 In this setting, availability of positive inotropic drugs with a neutral profile on cardiac rhythm and anti-ischemic effects would confer benefits.
K ATP Channel Opening
Levosimendan opens both mitochondrial 87, 88 and sarcolemmal 89,90 K ATP channels. Although the definite relevance of these actions is unknown, opening of mitochondrial K ATP channel has repeatedly been implicated in mediation of anti-ischemic actions. 91 Prevention of mitochondrial Ca 2ϩ overload, restoration and stabilization of mitochondrial membrane potential, preservation of high-energy phosphates, and regulation of mitochondrial matrix volume have been proposed as underlying mechanisms. 92 Interestingly, the positive inotrope levosimendan protected ischemic myocardium, 85,93 decreased myocardial infarct size when administered before and during myocardial ischemia in dogs, 61 and improved survival compared with placebo in patients with LV failure complicating acute myocardial infarction. 51 Opening of sarcolemmal K ATP channels, however, has been implicated in both mediating cardioprotective effects 94 and exerting a theoretical proarrhythmic potential. 95 This detrimental action on heart rhythm is produced by the large outward repolarizing K ϩ current that sarcolemmal K ATP channel opening initiates. Subsequent hyperpolarization of resting membrane potential and shortening of action potential duration decreases the effective refractory period 96 of the tissue and thereby increases the susceptibility to reentrant arrhythmias. Although levosimendan indeed hyperpolarized membrane potential, 89 shortened action potential duration in isolated cells, 90 and slightly shortened effective refractory period in patients, 97 experimental and clinical studies so far have demonstrated a neutral effect of this drug on heart rhythm rather than proarrhythmic potential. 13, 85, 97 Effects of Levosimendan during Ischemia, Stunning, and Myocardial Infarction Because levosimendan does not increase myocardial oxygen demand 81 and possibly exerts anti-ischemic effects, 61, 93, 98 efficacy and safety of this substance have been intensively tested before, during, and after ischemia-reperfusion injury in experimental and clinical studies. Levosimendan did not promote ischemia-reperfusion arrhythmias compared with dobutamine in guinea pig hearts 85 and in patients with stable moderate-to-severe ischemic cardiomyopathy when used in recommended clinical concentrations (6-to 24-g/kg bolus over 10 min, followed by an infusion of 0.05-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in a double-blinded, placebo-controlled, randomized, multicenter study. 45 Furthermore, the incidence of arrhythmias was not increased when levosimendan was compared with placebo in patients with acute myocardial infarction 51 or administered perioperatively in patients with coronary artery bypass grafting. 75 Although obviously having a neutral profile on heart rhythm, levosimendan consistently improved contractile function in the setting of global ischemia-reperfusion injury in experimental 85, 93, 99, 100 and clinical studies. 11, 51, 75 In contrast, two experimental studies using regional myocardial ischemia in pigs demonstrated detrimental effects of levosimendan during ischemia, i.e., increase in the rate of ventricular arrhythmias 101 and worsening of the myocardial contractile function in the ischemic area. 102 An increased frequency of ventricular arrhythmias was also noted at levosimendan doses of 0.6 g ⅐ kg Ϫ1 ⅐ min Ϫ1 (i.e., 3 times higher than upper recommended dose) in patients with stable ischemic cardiomyopathy. 45 The reasons for these findings may be related to a decline in coronary perfusion pressure, redistribution of coronary blood flow producing coronary steal, and increase in myocardial oxygen consumption due to PDE III inhibition. 103 Therefore, as with any other positive inotropic drug, caution is advised with the use of levosimendan, especially in high doses, in patients who have ongoing myocardial ischemia.
Efficacy and safety of levosimendan have been demonstrated during states of myocardial stunning in experimental settings 104, 105 and in patients with acute coronary syndrome undergoing angioplasty in a randomized, double-blinded, placebo-controlled trial. 11 Administra-tion of levosimendan before or during myocardial stunning is of special interest not only because of the myofilament Ca 2ϩ sensitization of this drug. The decrease in myofilament responsiveness that characterizes stunning can also be prevented by ischemic preconditioning. 24 Because opening of myocardial K ATP channels plays a key role in the mediation of ischemic preconditioning, one may speculate that administration of the K ATP channel opener levosimendan before ischemia may also prevent or attenuate the negative effects of myocardial stunning. Levosimendan also has cardioprotective effects by opening K ATP channels in dogs with acute myocardial infarction. In this setting, levosimendan decreased myocardial infarct size while producing positive inotropic effects. These protective actions were blocked with glibenclamide without alteration of the hemodynamic effects of levosimendan. 61
Pharmacokinetics, Metabolism, and Dosage
The pharmacologic profile of levosimendan and its metabolites in patients with normal and compromised myocardial contractile function has been reviewed extensively elsewhere. 106 Important pharmacokinetic data of levosimendan in healthy volunteers and patients with congestive heart failure are shown in table 1.
Pharmacokinetics
Although during CHF pharmacokinetics of many drugs may be altered because of reduction of central volume, fluid retention, and reduced blood flow to various organs, including liver and kidneys, 107 pharmacokinetic parameters of intravenous levosimendan are comparable when obtained in healthy volunteers and patients with mild 108 or NYHA functional class III or IV heart failure. 44 Levosimendan has a ␤ elimination half-life, volume of distribution, and total body clearance of approximately 1 h, 20 l, and 300 ml/min, respectively. These parameters remain constant independent of the duration of infusion. 71 Because levosimendan at a pH of 7.4 is present primarily in the ionized form (pKa 6.26) and is 98% bound to plasma proteins, only trace amounts of the unchanged drug are found in erythrocytes and urine. 108 
Metabolism
The extensive metabolism of levosimendan yields biologically active metabolites (e.g., OR-1855, OR-1896) that are eliminated in urine and feces. The clinically most relevant metabolite, OR-1896, also has Ca 2ϩ -sensitizing and weak PDE III-inhibiting properties 49 and exerts positive inotropic effects similar to the parent compound. 109 OR-1896, however, has an elimination half-life of 80 -96 h, 48 reaches maximum plasma concentrations approximately 2 days after withdrawal of a 24-h infusion of levosimendan in patients with CHF ( fig. 4) , and is likely to be responsible for the sustained or greater hemodynamic effects observed after discontinuation of levosimendan. 48, 50 Because of this accumulation of OR-1896, intravenous administration of levosimendan is therefore currently approved for 24 h. The effects of continuous infusions exceeding 24 h on plasma levels of levosimendan and its circulating metabolites and possible desired and undesired side effects, however, have recently been repeatedly investigated. 50, 71, 110 Pharmacokinetics of levosimendan were similar after single-dose administration and continuous infusion of 7 days, 110 whereas accumulation of OR-1896 was confirmed. 71 An extended infusion of 0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 over 7 days decreased systolic blood pressure (11 Ϯ 14 mmHg) and substantially increased heart rate (26 Ϯ 19 beats/min) on day 7 but was nevertheless well tolerated in patients 
Fig. 4. Plasma concentrations of levosimendan and its metabolites, OR-1855 and OR-1896, during and after a 24-h infusion of levosimendan in patients with chronic heart failure. Concentrations of levosimendan decline quickly after discontinuation of the infusion, whereas both metabolites reach maximum plasma concentrations approximately 2 days after withdrawal of levosimendan.
Error bars indicate SEMs. Reprinted with permission from Dustri-Verlag, Inc., from Kivikko et al. 48 with NYHA functional class III or IV symptoms of heart failure and ejection fractions below 40%. 71 
Dosage
Administration of a 6-to 24-g/kg bolus dose of levosimendan followed by a 24-h infusion of 0.05-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 produces plasma concentrations of 10 -100 ng/ml (0.035-0.35 M) in patients with NYHA functional class II-IV heart failure 44 and can be considered as the therapeutic range to obtain favorable hemodynamic effects. 45 
Safety Issues
Levosimendan generally is well tolerated by patients with moderate or severe heart failure, with an overall frequency of adverse events of 17-29%, which is similar to that of placebo (17-20%). 45, 51, 58 
Interaction with Concomitant Heart Failure Drugs
In most clinical trials that evaluated the effects of levosimendan in heart failure, patients were taking concomitant routine heart failure drugs. 14, 45, 51, 58 For example, in a randomized multicenter trial, 89% of patients receiving levosimendan were using angiotensin-converting enzyme (ACE) inhibitors, 95% were using diuretics, 76% were using digoxin, and 37% were using ␤ blockers. 14 Although additive responses particularly regarding vasodilation (i.e., ACE inhibitors and levosimendan) and heart rate (i.e., nitrates or ␤ blockers and levosimendan) would be expected, clinical studies so far have not reported serious interactions when levosimendan was used within the recommended dose range and in patients with myocardial contractile impairment.
A subgroup analysis evaluating the concomitant effect of ␤ blockade on hemodynamics revealed no reduction of the effects of levosimendan on cardiac output and PCWP, whereas the actions of dobutamine were attenuated. 14 This finding is in agreement with previous preclinical and clinical data demonstrating beneficial or neutral effects of parallel atenolol 47 or carvedilol 111 administration on the inotropic effects of levosimendan.
In another double-blinded, randomized, multicenter trial, the majority of patients received ACE inhibitors (5-20 mg enalapril), nitrates, and diuretics when various dose regimes of levosimendan were compared with dobutamine or placebo. 45 Although no direct comparisons were made between patients with or without these drugs, treatment with levosimendan within the recommended doses (0.05-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in general was associated with only minor decreases in mean arterial blood pressure (3.5 Ϯ 2.8 mmHg) after 24 h of treatment. Similarly, 50 mg captopril did not further decrease systolic or diastolic blood pressures when administered concomitantly with levosimendan in patients with NYHA functional class II or III after previous myocardial infarction. 112 Although no major additive hemodynamic effects of the combination of levosimendan and isosorbide-5-mononitrate compared with each drug alone were observed in healthy subjects at rest, an exaggerated circulatory response during an orthostatic test (i.e., increase in heart rate by 40 beats/min; inability to stand upright) was observed with this combination of drugs. 113 In contrast, concomitant nitrate therapy in patients with acute myocardial infarction produced only marginal decreases in systolic blood pressure (5 mmHg) and minor increases in heart rate (4 beats/min). 51 Similarly, 5 mg felodipine, a dihydropyridine calcium antagonist, combined with oral levosimendan did not further increase heart rate and had no effect on blood pressure. 114 No exaggerated or attenuated hemodynamic side effects of levosimendan were further reported in the presence of furosemide (10 mg/h) and amiodarone. 73 Hemodynamic Side Effects Dose-dependent increases in heart rate and decreases in mean arterial blood pressure and total peripheral and pulmonary vascular resistance 45 may cause a variety of unfavorable hemodynamic effects, including myocardial ischemia, hypotension, cardiac arrhythmias, and hypoxemia. Treatment within the recommended doses of levosimendan, however, does not induce myocardial ischemia 45, 51 and symptomatic or asymptomatic hypotension (Ͼ 10-mmHg pressure decrease). 51 Levosimendan-induced vasodilation may, however, be responsible for the increased frequency of headache, dizziness, and nausea observed in several clinical trials. 14, 45, 113 Electrophysiologic Side Effects Short-term intravenous administration (18-g/kg bolus followed by 0.4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) increases heart rate, shortens sinus node cycle duration and sinus node recovery time, and decreases atrioventricular nodal conduction interval and refractory periods. 115 These actions indicate that levosimendan enhances impulse formation and conduction, accelerates the recovery of excitability, and therefore may also increase the ventricular response rate during atrial fibrillation. Several clinical studies including patients with atrial fibrillation, however, have been performed, 45, 48, 51, 71 and so far, no adverse effects related to this rhythm disorder have been reported.
Levosimendan may prolong the rate-corrected QT interval (QTc), depending on dose, duration of administration, patient profile, and mode of calculation. When used in recommended doses (12 g/kg over 10 min followed by an infusion of 0.05-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), the QTc interval remained unaffected. 45 Single-bolus injections of 6.5 and 25 g/kg without subsequent continuous infusion in healthy men produced QTc prolongations as assessed by the Bazett equation of ϩ6 ms and ϩ21 ms, respectively. 116 In contrast, administration of bolus doses of 24 and 36 g/kg followed by continuous infusions of 0.4 and 0.6 g ⅐ kg Ϫ1 ⅐ min Ϫ1 prolonged QTc duration by 15 Ϯ 20 and 45 Ϯ 10 ms in patients with NYHA functional class II-IV heart failure. 45 Continuous infusions of levosimendan in doses of 0.05-0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 but over 7 days increased mean QTc values by 38 Ϯ 42 and 52 Ϯ 40 ms. 71 The impact of this proarrhythmic potential of levosimendan must be weighed against possible antiarrhythmic actions due to the lack of cytosolic Ca 2ϩ accumulation, maintenance of diastolic coronary blood flow, and neutral effect on myocardial oxygen consumption. To date, there is no evidence of an increase in the development of new supraventricular or ventricular tachyarrhythmias, including torsade de pointes, in healthy volunteers and patients with severe heart failure, suggesting little potential for the drug to provoke life-threatening proarrhythmic reactions. 13 Other Side Effects Serum potassium levels, 45 erythrocyte count, and hemoglobin and hematocrit values may slightly decrease after prolonged levosimendan infusion, 71 suggesting a routine control and correction of these parameters in clinical practice.
Clinical Trials with Possible Indications for Levosimendan
Currently, administration of levosimendan is approved for short-term treatment of acute decompensated CHF when conventional therapy with diuretics, ACE inhibitors, and digitalis is insufficient and inotropes are required. In addition, because of its interesting pharmacologic profile, several other possible indications for levosimendan have recently been explored, and the encouraging results of these trials may place levosimendan as a valuable expansion or replacement of standard therapy in the future.
Acute Decompensation of CHF
The LIDO study, a randomized, double-blinded, multicenter trial, compared the effects of levosimendan with dobutamine in 203 patients with acute decompensated low-output heart failure. 14 These patients had an LV ejection fraction of less than 35%, a cardiac index of less than 2.5 l ⅐ min Ϫ1 ⅐ m Ϫ2 , and a PCWP or 15 mmHg or greater on the basis of deterioration of severe CHF, heart failure after cardiac surgery, or acute heart failure related to a cardiac or noncardiac disorder of recent onset. A bolus of levosimendan of 24 g/kg was infused over 10 min, followed by a continuous infusion of 0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for 24 h. Dobutamine was infused for 24 h at an initial dose of 5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 without a bolus. The infusion rate of each drug was doubled (i.e., 0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 levosimendan and 10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 dobutamine) if the response was inadequate at 2 h. The primary endpoint was the proportion of patients with hemodynamic improvement (i.e., increase of cardiac output of 30% or more and decrease of PCWP of 25% or more) at 24 h. All-cause mortality was assessed prospectively at 31 days and retrospectively at 180 days after randomization. Levosimendan treatment was superior to dobutamine in increasing cardiac output and decreasing PCWP ( fig. 3) , and a significantly greater proportion of patients in the levosimendan group achieved the primary endpoint compared with the dobutamine group (28% vs. 15%; P ϭ 0.022). Although overall frequency of adverse events was similar, headache tended to be associated more frequently with levosimendan, whereas rhythm disorders and myocardial ischemia were more common with dobutamine. Administration of levosimendan was associated with both a significantly lower 31-day (8% vs. 17%; P ϭ 0.049) and 180-day (26% vs. 38%; P ϭ 0.029) mortality ( fig. 5 ). Interestingly, levosimendan was equally effective in patients with concurrent ␤-blocker therapy, whereas the actions of dobutamine were attenuated, as expected. Interpretation of these encouraging results must include consideration that comparable hemodynamic effects might have also been achieved with higher infusion rates of dobutamine (although possibly with higher adverse events) and that, because of the lack of a placebo group, it cannot be derived whether this was a true beneficial effect of levosimendan or rather reflected a more adverse effect of dobutamine.
Beneficial hemodynamic effects of levosimendan were also observed in a 6-h short-term treatment of 146 patients with acute decompensated ischemic or dilated cardiomyopathy in a multicenter, double-blinded, placebo-controlled trial. 58 In these patients with NYHA func- 14 tional class III or IV symptoms of heart failure and ejection fractions of 30% or less, levosimendan therapy was initiated with a bolus dose of 6 g/kg, followed by a continuous infusion of 0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 . At hourly intervals, a repeat bolus of 6 g/kg was given, and the infusion rate was up-titrated by increments of 0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 until a maximum rate of 0.4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 was achieved or a dose-limiting event (i.e., heart rate Ͼ 130 beats/min or increase in heart rate of Ͼ 15 beats/min, symptomatic hypotension or a decrease in systolic blood pressure to Ͻ 75 mmHg, decrease in PCWP to Յ 10 mmHg) occurred. The primary endpoint was the proportion of patients with an increase in stroke volume or a decrease in PCWP of 25% or more at 6 h. Levosimendan dose-dependently increased LV stroke volume (maximum 28% with the highest dose), cardiac index (maximum 39%), and heart rate (maximum 8%) and decreased PCWP (maximum 6 Ϯ 1 mmHg) when compared with placebo.
Inotropic Support during and after Myocardial Ischemia
Safety, efficacy, and effects on mortality of various doses of levosimendan were investigated in the RUSS-LAN study, when this drug or placebo was administered in 504 patients with LV failure complicating acute myocardial infarction in a randomized, double-blinded, multicenter trial. 51 In this investigation, four different dosing regimens of levosimendan were tested (6-to 24-g/kg bolus infused over a period of 10 min, followed by 6 h infusions of 0.1-0.4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ). At the time of levosimendan administration, most patients were using nitrates and diuretics, approximately 40% were using ACE inhibitors or ␤ blockers, and 17% had received thrombolysis. None of the patients had received percutaneous transluminal coronary angioplasty or coronary artery bypass grafting. In the highest dosing group (24g/kg bolus followed by 0.4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), a trend toward higher frequency of ischemia and hypotension was observed, but these effects were not evident at lower doses (0.1-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Levosimendantreated patients in general experienced a lower risk of death and worsening heart failure than patients receiving placebo during both the 6-h infusion (2.0% vs. 5.9%) and over 24 h (4.0% vs. 8.8%; P ϭ 0.044). Furthermore, all-cause mortality among levosimendan-treated patients was significantly lower than with placebo for the 14-day period after the start of treatment (11.7% vs. 19.6%; P ϭ 0.031) and exhibited a trend toward reduced mortality after 180 days of follow-up (22.6% vs. 31.4%; P ϭ 0.053). This study suggests that levosimendan infusions of 0.1-0.2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 are favorable compared with higher doses, because they combine a low potential of side effects with a maintained positive effect on survival in patients with LV failure complicating acute myocardial infarction.
Although levosimendan also produced significantly fewer ischemic adverse side effects compared with dobutamine in the LIDO study, 14 did not aggravate ischemia in patients with stable coronary heart disease as assessed by a 24-h Holter electrocardiogram, 114 and enhanced cardiac output in patients with ischemic heart disease and LV dysfunction, 69 caution may be advised when this drug is administered in patients with critical coronary stenoses and regional myocardial ischemia. In this setting, despite improvement of overall contractile function, animal experiments demonstrated detrimental effects of levosimendan 101,102 that may have been due to declines in coronary perfusion pressure producing failure of autoregulation, coronary steal, or increased mechanical stress of myocytes between ischemic and nonischemic areas. 103 
Myocardial Stunning after Percutaneous Transluminal Coronary Angioplasty in Patients with Acute Coronary Syndrome
Improvement of the function of stunned myocardium after percutaneous transluminal coronary angioplasty was shown after infusion of levosimendan in 24 patients with acute coronary syndrome in a double-blinded, randomized, placebo-controlled trial. 11 Levosimendan (24 g/kg over 10 min) was administered 10 min after successful coronary angioplasty, and LV and regional functions were assessed by pressure-volume loops and Slager wall motion analysis, respectively. In levosimendan-treated patients, systolic function improved and the number of hypokinetic segments decreased from 8.9 Ϯ 0.9 to 6.5 Ϯ 1.1 when compared with placebo (7.8 Ϯ 1.0 to 8.5 Ϯ 1.1). This action occurred without parallel impairment of diastolic function.
Cardiac Surgery
Although the efficacy of levosimendan has repeatedly been demonstrated in the perioperative setting, the number of patients investigated was rather small. 14, 74, 117 In a randomized, double-blinded, placebo-controlled study, levosimendan (18-or 36-g/kg bolus and 0.2-or 0.3-g ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion) administered 15 min before separation of cardiopulmonary bypass and continued for 6 h had beneficial effects on cardiac performance in low-risk patients and had no detrimental effects on arterial oxygenation and perioperative arrhythmias. 75 In this study, administration of the 36g/kg bolus instantly increased heart rate, although this effect vanished after 1 h despite continuation of the infusion. Similarly, levosimendan (8 or 24 g/kg administered as a 5-min bolus without continuous infusion) improved hemodynamic parameters without changing myocardial oxygen consumption or substrate extractions after coronary artery bypass grafting in patients with ejection fractions greater than 30%. 39 The high dose but not the low dose of levosimendan increased heart rate (maximum 11 beats/min) during the observation period of 1 h. In the setting of off-pump coronary artery bypass surgery, increases in stroke volume and cardiac output and decreases in systemic vascular resistance were observed when levosimendan was administered in two different bolus doses (12 or 24 g/kg over 10 min) 20 min before the start of surgery in patients with normal preoperative ventricular function. Heart rate increased in both levosimendan-treated groups during the observation period of 1 h, whereas no differences in mean arterial blood pressure were demonstrated compared with placebo. 118 
Cardiogenic Shock
In the presence of refractory cardiogenic shock (defined as cardiac index Ͻ 2.2 l ⅐ min Ϫ1 ⅐ m Ϫ2 , PCWP Ͼ16 mmHg, systolic blood pressure Ͻ 90 mmHg, and requirement of catecholamines), 0.1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 levosimendan for 24 h as add-on therapy favorably altered hemodynamic parameters by increasing cardiac index from 1.8 Ϯ 0.4 to 2.4 Ϯ 0.6 l ⅐ min Ϫ1 ⅐ m Ϫ2 and decreasing systemic vascular resistance from 1,559 Ϯ 430 dyn · s · cm Ϫ5 to 1,109 Ϯ 202 dyn · s · cm Ϫ5 , although it was administered without administration of a bolus in 10 patients. No significant changes in mean arterial blood pressure (78 mmHg to 73 mmHg), heart rate (96 to 101 beats/min), or adverse events were observed in this uncontrolled, retrospective study. 72 Similarly, in a case series of 10 patients with cardiogenic shock undergoing emergency surgical revascularization, levosimendan in addition to standard catecholamines produced favorable effects. 74 
Right Ventricular Dysfunction
Because levosimendan decreased PCWP more effectively than dobutamine, 14 the substance may be of value in patients with reversibly increased pulmonary pressures or right ventricular dysfunction, e.g., in patients during and after heart transplantation. Using dynamic positive emission tomography, pulmonary artery catheterization, and echocardiography, improved right ventricular mechanical efficiency (ϩ24%) was demonstrated after administration of an 18-g/kg bolus and a 0.3-g ⅐ kg Ϫ1 ⅐ min Ϫ1 continuous infusion of levosimendan in eight patients with NYHA functional class III or IV symptoms of heart failure in a double-blinded, crossover, placebo-controlled study. 81 Although clinical data are sparse, administration of levosimendan with positive inotropic effects and parallel decreases in pulmonary pressures is promising in the setting of right ventricular dysfunction 119 and could confirm the encouraging results of animal studies 80 in this setting.
Combination with Other Positive Inotropic Drugs
Numerous reports of the efficacy of levosimendan as add-on therapy to catecholamines exist regarding improve-ment in hemodynamic parameters 68, 72, 74, 117, 120, 121 ; clinical data evaluating specific combinations at specific doses, however, are lacking. Efficacy of addition of levosimendan (6-g/kg bolus plus 0.2-g ⅐ kg Ϫ1 ⅐ min Ϫ1 continuous infusion for 24 h) was shown in patients with NYHA functional class IV heart failure refractory to a continuous infusion of dobutamine (10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) and furosemide. 73 In this study, combination of these positive inotropic drugs improved hemodynamics (increase in cardiac index 1.19 Ϯ 0.66 l ⅐ min Ϫ1 ⅐ m Ϫ2 and decrease in PCWP 5.4 Ϯ 8.7 mmHg) and consistently alleviated symptoms than when compared with dobutamine alone (increase in cardiac index 0.44 Ϯ 0.32 l ⅐ min Ϫ1 ⅐ m Ϫ2 and increase in PCWP 1.0 Ϯ 4.4 mmHg) after 24 h. This investigation confirmed an experimental study in conscious dogs that demonstrated superiority of a combination therapy of dopamine and levosimendan (i.e., levosimendan potentiated the positive inotropic effects of dopamine while attenuating its deleterious action on chamber compliance) over treatment with dopamine alone. 122 Furthermore, addition of levosimendan to epinephrine during profound acidosis improved the attenuated efficacy of epinephrine in guinea pig hearts. 123 Other Possible Indications Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone were evaluated in 36 patients in NYHA functional class IV who were resistant to a 24-h continuous infusion of dobutamine in an uncontrolled, nonrandomized trial. The 45day survival rates were 6% and 61% in patients treated with weekly dobutamine infusions and biweekly levosimendan infusions, respectively. 124 Data regarding the use of levosimendan in children, pregnancy, and circulatory failure due to septic shock are rare, but published experience gives an encouraging view beyond the treatment of acutely decompensated CHF. 80, [82] [83] [84] 121, [125] [126] [127] 
Economics
Currently, the clinically recommended administration of levosimendan is a single 24-h infusion, which is usually performed using one 12.5-mg vial with an average cost of approximately €700 ($875).
A cost-effectiveness analysis was performed for intravenous treatment with levosimendan compared with dobutamine in patients with severe low-output heart failure based on the data of the LIDO study. 128 Costs were based on study drug usage and hospitalization in the 6-month follow-up of the study, and the primary effectiveness measure was the gain in life expectancy. The mean survival in the LIDO study over 6 months was extrapolated (157 Ϯ 52 and 139 Ϯ 64 days for levosi-mendan-and dobutamine-treated patients, respectively). This assumed a mean additional lifetime of 3 yr based on the CONSENSUS trial 129 due to the similar patient population, and the gain in life expectancy was estimated at 0.35 yr/patient. Levosimendan increased the mean cost per patient by €1,108, which was attributable to the cost of the drug. Although the absolute difference in drug costs was relatively high (€1,024 vs. €41 for one treatment of levosimendan vs. dobutamine), the incremental cost per life-year saved was only €3,205 on European average, which is well below the acceptable threshold for cardiology therapies. Although the patients in the levosimendan group were alive for more days and thus at risk for a longer period of hospitalization, there was no increase in resource utilization with levosimendan treatment compared with dobutamine.
Conclusion
Levosimendan is a positive inotropic drug with vasodilating properties that has been extensively investigated in experimental studies and that is also increasingly the subject of clinical trials. Clinical trials that are currently under way in the United States (REVIVE study) and in Europe (SURVIVE study) aim to establish the role of levosimendan in short-and long-term therapy of patients with CHF. To date, clinical experience with levosimendan is encouraging because it combines several beneficial actions that considerably differ from other cardiotonic drugs. First, levosimendan enhances myocardial force without increasing intracellular Ca 2ϩ concentrations, which, in context with neutral effects on myocardial oxygen demand and heart rhythm, should be of benefit compared with catecholamines or PDE III inhibitors. Second, levosimendan does not impair myocardial relaxation, a possible limitation of other Ca 2ϩ sensitizers. Third, stimulation of ATP-sensitive potassium channels improves coronary blood flow, reduces preload and afterload, and may exert anti-ischemic actions. Finally, the drug has advantages on short-and long-term survival compared with standard inotropes and is safe, with a low incidence of adverse effects when used in appropriate concentrations. Therefore, part of the benefit of levosimendan may also be achieved because it allows other inotropic agents that may have adverse effects on clinical outcome to be reduced in dose or avoided.
